Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Proof of Principle Study Evaluating the Effects of Gonyautoxins, Paralytic Shellfish Poisoning (PSP) NEURO SERUM, on Objective and Subjective Symptoms of Chemotherapy-induced Peripheral Neuropathy (CINP)

NCT05052398 is registered in ClinicalTrials.gov with Algenis SpA as lead sponsor.

NCT NCT05052398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05052398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Proof of Principle Study Evaluating the Effects of Gonyautoxins, Paralytic Shellfish Poisoning (PSP) NEURO SERUM, on Objective and Subjective Symptoms of Chemotherapy-induced Peripheral Neuropathy (CINP)
Lead sponsor
Algenis SpA
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 14, 2021
Completion date
July 14, 2025
Enrollment
52 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced peripheral neuropathy